Sugitani Iwao, Nagaoka Ryuta, Saitou Marie, Sen Masaomi, Kazusaka Hiroko, Matsui Mami, Abe Takeshi, Ito Ryo, Toda Kazuhisa
Department of Endocrine Surgery, Nippon Medical School, Tokyo, Japan.
Division of Head and Neck, Cancer Institute Hospital, Tokyo, Japan.
World J Surg. 2025 Jan;49(1):159-169. doi: 10.1002/wjs.12417. Epub 2024 Nov 26.
Active surveillance (AS) for low-risk papillary thyroid carcinoma (PTC) is acknowledged as a valid management strategy. While older age is identified as a favorable factor for progression, long-term evidence is scarce and lifelong monitoring has been deemed essential. This study investigated progression patterns and tumor calcification under long-term AS and explored the possibility of ending follow-up.
A total of 650 patients with low-risk PTC who chose AS were enrolled. Progression was defined as either tumor enlargement (≥3 mm from initiation) or development of clinically apparent lymph node metastasis.
The median observation period was 8 years; 45.2% were under surveillance for ≥10 years. Overall, 80 patients (12.3%) exhibited progression. Median age and observation period at the time of progression were 55 and 4 years, respectively. Only 2 patients showed progression after 15 years of follow-up and 5 patients showed progression after reaching 80 years old. Among 71 patients experiencing tumor enlargement, surgery was performed immediately in 32 patients. The remaining 39 patients continued surveillance, but only 5 demonstrated ongoing enlargement thereafter. Of 40 surgeries due to progression, 36 were conducted within the first 10 years. The degree of calcification correlated with age and observation periods. No progression occurred after the development of rim calcification.
Progression during AS was extremely rare in older patients with long-term surveillance and in tumors with rim calcification. It may be feasible to consider ending scheduled surveillance visits for these patients. Instances of progression halting after enlargement are not uncommon.
对低风险乳头状甲状腺癌(PTC)进行主动监测(AS)被认为是一种有效的管理策略。虽然年龄较大被认为是疾病进展的有利因素,但长期证据稀缺,且终身监测被视为必不可少。本研究调查了长期AS下的疾病进展模式和肿瘤钙化情况,并探讨了终止随访的可能性。
共纳入650例选择AS的低风险PTC患者。疾病进展定义为肿瘤增大(起始后≥3毫米)或出现临床明显的淋巴结转移。
中位观察期为8年;45.2%的患者接受监测≥10年。总体而言,80例患者(12.3%)出现疾病进展。进展时的中位年龄和观察期分别为55岁和4年。只有2例患者在随访15年后出现进展,5例患者在80岁后出现进展。在71例肿瘤增大的患者中,32例立即接受了手术。其余39例患者继续监测,但此后只有5例显示肿瘤持续增大。在因疾病进展而进行的40例手术中,36例在最初10年内进行。钙化程度与年龄和观察期相关。边缘钙化出现后未发生疾病进展。
在长期监测的老年患者和有边缘钙化的肿瘤中,AS期间的疾病进展极为罕见。对于这些患者,可以考虑终止定期监测。肿瘤增大后进展停止的情况并不少见。